INTRODUCTION
Skeletal muscle (SKM) comprises 35-45% of the human body mass and is necessary for movement, posture, support and temperature regulation. SKM atrophy, a loss in muscle mass and strength, can be induced by numerous stimuli: disease (e.g., cancer cachexia, sepsis, HIV/AIDS, diabetes), injury (spinal cord damage, denervation), immobilization, fasting, ageing and glucocorticoid treatment 1, 2 . Muscle loss is attributable to either a decreased protein synthesis, increased protein degradation or some combination of both of these events. The extent to which each contributes to muscle loss varies with animal model, the evoking stimulus, study time course and muscle fiber type 2, 3, 4 . The protein degradation that produces atrophy results primarily from the activity of three proteolytic systems: calpains, cathepsins and the ubiquitin proteasome pathway (UPP). It is reported that the UPP is the primary proteolytic system involved 5 and is purported to be responsible for as much as 75% of the protein degradation that occurs during SKM atrophy 1, 6, 7 . The UPP is a multistep pathway requiring activation of an ubiquitin protein by an ubiquitin-activating enzyme (E1) and ATP hydrolysis. The activated ubiquitin is transferred to the ubiquitin-carrier protein (E2) which binds to an ubiquitin protein ligase (E3 ligase) carrying a protein substrate. The E3 ligase then transfers the ubiquitin to the targeted substrate. Once a substrate carries (a minimum of four) ubiquitin molecules, it is degraded by the 26S proteasome 1, 6, 7 . The basic mechanistic nature of the UPP has been described, but the specific players vary as do the signaling pathways that lead to transcription and translation of these players. To date, two muscle specific ubiquitin E3 ligases have been described: Muscle atrophy F-box (MAFbx/Atrogin1) and Muscle RING Finger-1 (MuRF1).
MAFbx/Atrogin-1 is a member of the SCF (Skp1, cdc53/Cullin and F-box protein) subfamily of ligases, containing an F-box domain which serves to bind the E3 complex to a targeted mERG Modulates MuRF Expression 5 protein 8, 9, 10 . MuRF1 belongs to the RING Finger E3 ligase subfamily which has a canonical Nterminal RING domain followed by a conserved region characteristic of the MuRF1 family and a zinc-finger domain 8, 11 . Expression of these E3 ligases has been shown to be variably modulated by both the PI3K/AKT/FOXO and the IKK-/IB-/Nfkappa B (NF-B) pathways, dependent upon animal model and the stimulus inducing the atrophic state 1, 2, 6, 7 . It has recently been shown that these two pathways are responsible for roughly half each of the muscle wasting that occurs in immobilization-induced SKM atrophy, demonstrating that they are the main pathways involved in this type of atrophy 12 .
The ether-a-gogo-related gene 1a (ERG1a) K + channel (Kv11.1, KCNH) produces the IKr current which is partially responsible for late phase repolarization of the cardiac action potential.
Mutations in this channel have been linked with Long QT Syndrome 2 (LQT2), a cardiac disorder characterized clinically by a prolonged QT interval, torsade de pointes and sudden cardiac death 13 . Two alternative splice variants of ERG1 have been cloned from human (HERG1A and 1B 14 ) and mouse (mERG1a and 1b 15 ) cDNA libraries and high levels of ERG1a and 1b expression have been detected in heart and brain of various mammals, including rats, mice and humans 14, 15, 16 . In previous studies with mice, we showed that the mERG1a homomultimeric channel is linked to SKM atrophy induced by hindlimb suspension (HS; i.e., an unloading model) and cancer cachexia 17 . Specifically, we showed that: 1) mERG1a channel protein level is upregulated in the gastrocnemius muscles (GM) of hindlimb suspended mice experiencing atrophy relative to matched muscles in weight bearing (WB) control mice; 2) ectopic expression of the wildtype (WT) mERG1a splice variant in SKM of WB mice induced atrophy while co-expression of the WT and a dominant negative mERG1a subunit (DNmERG1a, G628S 18 ) blocked atrophy in these mice; 3) ectopic expression of the DN-merg1a Hindlimb Suspension (HS). Custom suspension cages were constructed as described previously 22 . Mice were placed in these cages resting in approximately a 30 head down tilt with their hindlimbs elevated so that they were unable to place any load on their hindlimbs. Control mice were kept in commercial mouse cages in a normal weight bearing state.
Tissue Sectioning, Staining and CSA Determination. GMs were embedded, cryo-sectioned (12 m) and stained for β-galactosidase (lacZ) activity as described earlier 17 . Images of sections were captured with a Leaf Micro-Lumina digital camera (Scitex; Tel-Aviv, Israel). The CSA (m 2 ) of each muscle fiber was determined using Image J (NIH; Bethesda, MD).
Plasmids. The mERG1a clone in pBK/CMV 15 sectioned and stained for lacZ activity as a marker for gene expression. Because a greater abundance (2X) of mERG1a than lacZ cDNA was injected, we assume that all myofibers staining for lacZ reporter activity also express mERG1a and that those myofibers not staining for lacZ activity are not expressing plasmid.
Study 3A. The left GMs of 49 mice (7 groups of 7) were injected with plasmid encoding lacZ (10 g) and a second plasmid encoding mERG1a (30 g) while the right GMs were injected with the lacZ plasmid (10 g) and an empty (control) plasmid (30 g), followed by electro-transfer. assayed for Renilla and firefly luciferase activities using a Dual Luciferase Reporter Kit (ProMega).
Study 4. Hindlimb suspension. Two groups of 3 mice each (n=6) were: 1) allowed to remain weight bearing; or 2) hindlimb suspended. After 7 days of treatment (day 7 is when our model induces significant levels of myofiber CSA decrease 17 ), the mice were killed and the GMs were harvested and used to prepare muscle protein samples (both muscles of one mouse composed a sample). Electro-transfer. The GMs of a group of 6 mice (n=6) were injected with DNA (left = 10 g lacZ and 30 g mERG1a; right leg = 10 g lacZ and 30 g empty control plasmid) and the legs were electroporated. Two muscles were combined to make a sample; that is, two left legs made one mERG1a treated sample and two right legs composed a control sample, etc. GMs of mice from both designs were homogenized and centrifuged as described. Aliquots of each protein sample were electrophoresed and immunoblotted with either MuRF1 or Atrogin1
antibody. MAFbx genes were all expressed in response to HS ( expression. Data. Indeed, as reported earlier 17 , the myofiber CSA was significantly decreased in the myofibers of the mERG1a injected legs expressing plasmid relative to the myofibers in the same leg not expressing plasmid and to both the expressing and non-expressing myofibers in muscles injected with lacZ and empty plasmid (Fig. 2) . The decrease in fiber size is attributable to mERG1a expression and is significant for 4 weeks; the mERG1a expressing myofiber CSAs are no longer significantly smaller than controls at 5 and 6 weeks after electrotransfer. results show that indeed mERG1a was expressed in response to mERG1a plasmid electrotransfer in the GMs (Fig. 3A) . Importantly, the MuRF1 E3 ligase gene was also expressed in response to the mERG1a expression and, although no significant differences from baseline transcript levels were detected at Days 1 or 2 post electrotransfer (Fig. 3A) , the data reveal that mERG1a and MuRF1 transcript levels both increased above Day 1 levels significantly by Day 3
and peaked at Day 4. Transcript levels for both genes declined toward baseline levels by day 7.
The data indicate that MuRF1 expression is increased by ectopic mERG1a expression. Most interestingly, there is no significant increase in MAFbx gene expression over the 7 days during which mERG1a was expressed, suggesting that ectopic expression of mERG1a did not activate this potential route for protein degradation. B. Rationale. To confirm that mERG1a expression does not affect MAFbx expression, we co-expressed mERG1a, a MAFbx luciferase reporter and a
Renilla luciferase reporter (as control for differences in transfection efficiencies) and assayed for dual luciferase activities 7 days later. Data. The ratio of firefly to Renilla luciferase activities was determined for each leg and the ratio of luciferase activity in the left to right legs was calculated for each mouse (Fig. 3B) . Although mice from a set of positive controls showed that mERG1a expression decreases levels of ubiquinated firefly luciferase (data not shown), in concert with expectations, MAFbx/Atrogin1 reporter luciferase activity was not significantly affected by mERG1a co-expression (Fig. 3B ). These studies confirm that mERG1a expression does not affect MAFbx expression. (Fig. 5A ). Muscle fiber CSA data demonstrate that, indeed, muscle fiber size decreases in response to mERG1a expression; however, this decrease in muscle fiber CSA is not affected by expression of HRFOXO3a (Fig. 5B ). These sets of data suggest that mERG1a does not modulate MuRF1 expression occurs in numerous species including mice 32 and rats 8, 33 . Unloading studies in humans also reveal changes in MuRF1 and MAFbx expression 34 and show that these changes differ according to which muscle is monitored and suggest, therefore, that E3 ligase expression may be fiber type specific 4, 35 . Nonetheless, the mechanism(s) responsible for these changes in E3 ligase abundances are not well understood.
Here we show that hindlimb suspension induces expression of mERG1a, MuRF1 and MAFbx. In fact, transcription of all the assayed genes occurs early in HS, prior to Day 7, at which time muscle fiber CSA is significantly smaller than in control WB mice 17 . However, while MuRF1 mRNA levels are correlated with mERG1a expression, MAFbx mRNA levels begin to rise prior to any noted increase in mERG1a mRNA levels, suggesting that at least initial MAFbx gene expression is likely not linked to HS induced mERG1a expression. Importantly, we demonstrate that ectopic expression of mERG1a indeed induces expression of MuRF1 in mouse GM. In fact,
MuRF1 expression mirrors that of electro-transferred mERG1a very closely, with mERG1a levels rising at day 3 prior to a sharp increase in MuRF1 mRNA levels between Days 3 and 4. production by inactivating some point of the PI3K/Akt pathway, then it could be acting through effects of PPAR- agonists on the membrane-bound PPAR- receptors. Of course, the work does not address potential effects on other pathways (e.g., NF-B factors), so it does not rule out that PPAR- activation is increasing MuRF1 (or MAFbx) expression through other activity(-ies).
PI3K/Akt independent mechanisms also have been shown to modulate FOXO activity. For example, Nemo-like kinase (NLK) has been shown to bind and phosphorylate FOXO1, thereby inhibiting its transcriptional activity through the PI3k/Akt independent transforming growth factor-beta-activated kinase (TAK1)-NLK pathway 39 . Further, Atrogin1 expression has been shown to be induced by a p38MAPK dependent pathway in cardiac myocytes, independent of the Akt/FOXO pathway 40 . These routes represent further possibilities for mERG1a modulation of MuRF1 expression.
IKK-/IB-/NF-B: Activation of NF-B family members by upstream IKK- activation leads to production of E3 ligases 2, 24, 37, 41 . In brief, some factor triggers activation of IKK- Nonetheless, given that mERG1a expression causes a significant increase in MuRF1 mRNA and protein levels and the fact that NF-B factors are known to be involved in MuRF1 expression, the data suggest that mERG1a could modulate NF-B factor expression and/or activity.
Identifying if/which NF-B factors are modulated by mERG1a and the mechanism(s) by which this occurs clearly requires study. not surprising given the facts that NF-B is basically required for disuse muscle atrophy 27, 37, 42 and that MuRF1 transcription, and not MAFbx, is increased by NF-B factors 37 . Obviously, the mechanism by which the mERG1a K + channel up-regulates MuRF1 expression in SKM needs further investigation along with the factors inducing up-regulation of the K + channel itself.
Investigation of the mechanism(s) initiating SKM atrophy is important because SKM atrophy is coincident with many pathological conditions and is related to increased disability, morbidity and mortality and understanding these pathways will suggest specific, more effective therapies for abatement of this debilitating condition. 
